Skip to main content

cefepime dihydrochloride monohydrate (RenapimeĀ®)

 

Following a limited submission

AWMSG advice

Status: Recommended with restrictions

Cefepime (Renapime®) is recommended as an option for restricted use within NHS Wales. Cefepime (Renapime®) is licensed for the treatment of infections caused by bacteria that are cefepime-sensitive:

  • lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis;
  • uncomplicated and complicated urinary tract infections, including pyelonephritis;
  • skin and subcutaneous infections;
  • intra-abdominal infections, including peritonitis and biliary tract infections;
  • gynaecological infections;
  • bacterial meningitis in infants and children;
  • in combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection;
  • treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cefepime (Renapime®) is restricted for use for resistant pseudomonas infections where first-line agents are not effective or contraindicated. Cefepime (Renapime®) is not recommended for use within NHS Wales outside of this subpopulation.

 Final Appraisal Recommendation (FAR): cefepime (Renapime) 4129 (PDF, 290Kb)
 AWMSG Secretariat Appraisal Report (ASAR): cefepime (Renapime )4129 (PDF, 83Kb)

Medicine details

Medicine name cefepime dihydrochloride monohydrate (RenapimeĀ®)
Formulation 1 g and 2 g powder for solution for injection / infusion
Reference number 4129
Indication

Treatment of infections caused by bacteria that are cefepime-sensitive:

  • lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis;
  • uncomplicated and complicated urinary tract infections, including pyelonephritis;
  • skin and subcutaneous infections;
  • intra-abdominal infections, including peritonitis and biliary tract infections;
  • gynaecological infections;
  • bacterial meningitis in infants and children;
  • in combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection;
  • treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Company Renascience Pharma Ltd
BNF chapter Infections
Submission type Limited
Status Recommended with restrictions
Advice number 1619
NMG meeting date 09/10/2019
AWMSG meeting date 13/11/2019
Date of issue 28/11/2019